Hepatology：感染HCV 2、3型青少年中索非布韦和利巴韦林的治疗效果

2017-06-08 MedSci MedSci原创

患有慢性丙型肝炎病毒(HCV)感染的儿童治疗方案有限。本研究评估联合口服索非布韦和利巴韦林在丙型肝炎病毒基因2型或3型，年龄在12-17岁青少年中的治疗效果。近期美国科学家发表研究性文章于著名肝脏病学杂志Hepatology以探讨这一问题。研究纳入52例接受索非布韦（400 mg、1次/天）和利巴韦林（2次/天）治疗12周（HCV基因2型）或24周（HCV基因3型）的患者。第7天采集最初入组10例

患有慢性丙型肝炎病毒(HCV)感染的儿童治疗方案有限。本研究评估联合口服索非布韦和利巴韦林在丙型肝炎病毒基因2型或3型，年龄在12-17岁青少年中的治疗效果。

近期美国科学家发表研究性文章于著名肝脏病学杂志Hepatology以探讨这一问题。研究纳入52例接受索非布韦（400 mg、1次/天）和利巴韦林（2次/天）治疗12周（HCV基因2型）或24周（HCV基因3型）的患者。第7天采集最初入组10例患者的血浆样本和在整个治疗过程中间隔取样所有患者的血浆样品评价索非布韦和其代谢物GS-331007的药物代谢动力学。主要疗效终点为治疗12周后，获得持续病毒学应答患者的比例。

患者平均年龄为15周岁，75%的患者为HCV基因3型。83%的患者之前未接受治疗，73%的患者经母婴传播感染丙肝。40%的患者无肝硬化，其余的患者未发生肝硬化。总体来说，98%（51/52，95%的可信区间为90%-100%）的患者获得持续病毒学应答，100%(13/13)的基因2型患者获得持续病毒学应答；97% (38/39)的基因3型患者获得持续病毒学应答。治疗12周，未获得病毒学应答的1例患者在治疗24周获得病毒学应答，随后失访。最普遍的不良反应是恶心（27%）和头痛（23%）。与二、三阶段sofobuvir试验中成人暴露相比，青少年中索非布韦和GS-331007的预定义药代动力学等效边界为50%-200%。

索非布韦和病毒唑/三唑核苷在丙型肝炎基因2型或3型的青少年患者中是安全有效的。

原始出处：Wirth S，et al. Sofosbuvir and Ribavirin in Adolescents 12 to 17 Years Old With Hepatitis C Virus Genotype 2 or3 Infection.Hepatology. 2017 May 22. doi： 10.1002/hep.29278.

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1893959, encodeId=61f11893959c3, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Jan 11 19:00:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257674, encodeId=4983125e674c5, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360302, encodeId=ab8a136030243, content=<a href='/topic/show?id=61073229696' target=_blank style='color:#2F92EE;'>#利巴韦林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32296, encryptionId=61073229696, topicName=利巴韦林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426743, encodeId=0e221426e43a7, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551347, encodeId=e48c155134e36, content=<a href='/topic/show?id=b8c4e6991d8' target=_blank style='color:#2F92EE;'>#索非布韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76991, encryptionId=b8c4e6991d8, topicName=索非布韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779614182697, createdName=howi, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208157, encodeId=a27720815e85, content=有收获，谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Jun 08 12:42:05 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
2018-01-11 jxrzshh

#治疗效果#

35 0
[GetPortalCommentsPageByObjectIdResponse(id=1893959, encodeId=61f11893959c3, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Jan 11 19:00:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257674, encodeId=4983125e674c5, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360302, encodeId=ab8a136030243, content=<a href='/topic/show?id=61073229696' target=_blank style='color:#2F92EE;'>#利巴韦林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32296, encryptionId=61073229696, topicName=利巴韦林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426743, encodeId=0e221426e43a7, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551347, encodeId=e48c155134e36, content=<a href='/topic/show?id=b8c4e6991d8' target=_blank style='color:#2F92EE;'>#索非布韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76991, encryptionId=b8c4e6991d8, topicName=索非布韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779614182697, createdName=howi, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208157, encodeId=a27720815e85, content=有收获，谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Jun 08 12:42:05 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
2017-06-10 ymljack

#HCV#

44 0
[GetPortalCommentsPageByObjectIdResponse(id=1893959, encodeId=61f11893959c3, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Jan 11 19:00:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257674, encodeId=4983125e674c5, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360302, encodeId=ab8a136030243, content=<a href='/topic/show?id=61073229696' target=_blank style='color:#2F92EE;'>#利巴韦林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32296, encryptionId=61073229696, topicName=利巴韦林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426743, encodeId=0e221426e43a7, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551347, encodeId=e48c155134e36, content=<a href='/topic/show?id=b8c4e6991d8' target=_blank style='color:#2F92EE;'>#索非布韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76991, encryptionId=b8c4e6991d8, topicName=索非布韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779614182697, createdName=howi, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208157, encodeId=a27720815e85, content=有收获，谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Jun 08 12:42:05 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
2017-06-10 meichuangyi

#利巴韦林#

40 0
[GetPortalCommentsPageByObjectIdResponse(id=1893959, encodeId=61f11893959c3, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Jan 11 19:00:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257674, encodeId=4983125e674c5, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360302, encodeId=ab8a136030243, content=<a href='/topic/show?id=61073229696' target=_blank style='color:#2F92EE;'>#利巴韦林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32296, encryptionId=61073229696, topicName=利巴韦林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426743, encodeId=0e221426e43a7, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551347, encodeId=e48c155134e36, content=<a href='/topic/show?id=b8c4e6991d8' target=_blank style='color:#2F92EE;'>#索非布韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76991, encryptionId=b8c4e6991d8, topicName=索非布韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779614182697, createdName=howi, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208157, encodeId=a27720815e85, content=有收获，谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Jun 08 12:42:05 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
2017-06-10 gwc384

#EPA#

42 0
[GetPortalCommentsPageByObjectIdResponse(id=1893959, encodeId=61f11893959c3, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Jan 11 19:00:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257674, encodeId=4983125e674c5, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360302, encodeId=ab8a136030243, content=<a href='/topic/show?id=61073229696' target=_blank style='color:#2F92EE;'>#利巴韦林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32296, encryptionId=61073229696, topicName=利巴韦林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426743, encodeId=0e221426e43a7, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551347, encodeId=e48c155134e36, content=<a href='/topic/show?id=b8c4e6991d8' target=_blank style='color:#2F92EE;'>#索非布韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76991, encryptionId=b8c4e6991d8, topicName=索非布韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779614182697, createdName=howi, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208157, encodeId=a27720815e85, content=有收获，谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Jun 08 12:42:05 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
2017-06-10 howi

#索非布韦#

49 0
[GetPortalCommentsPageByObjectIdResponse(id=1893959, encodeId=61f11893959c3, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Jan 11 19:00:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257674, encodeId=4983125e674c5, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360302, encodeId=ab8a136030243, content=<a href='/topic/show?id=61073229696' target=_blank style='color:#2F92EE;'>#利巴韦林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32296, encryptionId=61073229696, topicName=利巴韦林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426743, encodeId=0e221426e43a7, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551347, encodeId=e48c155134e36, content=<a href='/topic/show?id=b8c4e6991d8' target=_blank style='color:#2F92EE;'>#索非布韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76991, encryptionId=b8c4e6991d8, topicName=索非布韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779614182697, createdName=howi, createdTime=Sat Jun 10 02:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208157, encodeId=a27720815e85, content=有收获，谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Jun 08 12:42:05 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
2017-06-08 清风拂面

有收获，谢谢

105 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

感染

Hepatology：感染HCV 2、3型青少年中索非布韦和利巴韦林的治疗效果

相关资讯

科室

工具

服务